Objective: The aim of this study is to investigate the trend of prescription drugs for children with ADHD in Japan. Method: Using health insurance claims data of 3,672,951 people between January 2005 and December 2015, we investigated the trend of prescription drugs for 7,856 children with ADHD. Results: After approval in 2007, the proportion of prescriptions for methylphenidate-osmotic-controlled release oral delivery system tablets was 31.4% in 2009 (adjusted odds ratio [AOR] = 2.72; 95% confidence interval [CI] = [2.12, 3.51]) and reached a plateau approximately after 2009 (AOR = 0.96; 95% CI = [0.94, 0.98]). The proportion of prescriptions for atomoxetine increased from 6.1% in 2008 to 21.8% in 2014 (AOR = 1.12; 95% CI = [1.13, 1.18]). The proportion of prescriptions for aripiprazole and ramelteon increased (all trend p < .001). Conclusion: Prescriptions of drugs for children with ADHD have changed. We need to monitor the safety of ADHD medications among children with ADHD.
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.
2.
BachmannC. J.WijaarsL. P.KalverdijkL. J.BurcuM.GlaeskeG.Schuiling-VeningaC. C. M.. . . ZitoJ. M. (2017). Trends in ADHD medication use in children and adolescents in five western countries, 2005–2012. European Neuropsychopharmacology, 27, 484-493.
3.
Beau-LejdstromR.DouglasI.EvansS. J. W.SmeethL. (2016). Latest trends in ADHD drug prescribing patterns in children in the UK: Prevalence, incidence and persistence. BMJ Open, 6, e010508.
4.
BolandF.GalvinR.ReulbachU.MotterliniN.KellyD.BeneettK.FaheyT. (2015). Psychostimulant prescribing trends in a pediatric population in Ireland: A national cohort study. BMC Pediatrics, 15, Article 118.
5.
CollinsK. P.ClearyS. D. (2015). Racial and ethnic disparities in parent-reported diagnosis of ADHD: National survey of children’s health (2003, 2007, and 2011). Journal of Clinical Psychiatry, 77, 52-59.
6.
CooperW. O.HabelL. A.SoxC. M.ChanK. A.ArbogastP. G.CheethamT. C.. . . RayW. A. (2011). ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine, 365, 1896-1904.
7.
Council on Environmental Health. (2012). Pesticide exposure in children. Pediatrics, 130, e1757-e1763.
8.
DavidovitchM.KorenG.FundN.ShremM.PorathA. (2017). Challenges in defining the proportions of ADHD diagnosis and treatment: Trends over the last decade. BMC Pediatrics, 17, Article 218.
9.
FukumizuM.HayashiM.MiyajimaT.IshizakiA.TanakH.KohyamaJ. (2015). A nationwide survey on the uses of melatonin and ramelteon in Japanese children. No to Hattatsu, 47, 23-27.
10.
GarfieldC. F.DorseyE. R.ZhuS.HuskampH. A.ContiR.DusetzinaS. B.. . . AlexanderG. C. (2012). Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000–2010. Academic Pediatrics, 12, 110-116.
11.
KimuraS.SatoT.IkedaS.NodaM.NakayamaT. (2010). Development of a database of health insurance claims: Standardization of disease classifications and anonymous record linkage. Journal of Epidemiology, 20, 413-419.
12.
KongA.FriggeM. L.MassonG.BesenbacherS.SulemP.MagnussonG.. . . StefanssonK. (2012). Rate of de novo mutations and the importance of father’s age to disease risk. Nature, 488, 471-475.
13.
MakinoK.SaitoK.KodairaM.AoshimaM.ItoC.IwadareY.WatanabeK. (2015). Expert consensus regarding the diagnosis and treatment of children with ADHD in Japan: Pharmacotherapy [Supplemental material]. Japanese Journal of Child and Adolescent Psychiatry, 56, 822-855.
14.
ManK. K. C.IpP.HsiaY.ChanE. W.ChuiC. S. L.LamM. P. S.WongI. C. K. (2017). ADHD drug prescribing trend is increasing among children and adolescents in Hong Kong. Journal of Attention Disorders, 21, 1161-1168.
15.
NissenS. E. (2006). ADHD drugs and cardiovascular risk. New England Journal of Medicine, 354, 1445-1448.
16.
NussbaumN. L. (2012). ADHD and female specific concerns: A review of the literature and clinical implications. Journal of Attention Disorders, 16, 87-100.
17.
ObaraT.SatohM.OobaN.MorikawaY.NishigoriH.ManoN. (2015). Prescription of drugs for children with attention-deficit/hyperactivity disorder (ADHD) in Japan: A study based on health insurance claim data. Journal of Drug Interaction Research, 39(2), 9-17.
18.
OkumuraY.FujitaJ.MatsumotoT. (2014). Trends of psychotropic medication use among children and adolescents in Japan data from the national insurance claims database between 2002 and 2010. Seishin Shinkeigaku Zasshi, 116, 921-935.
19.
PliszkaS. R.CrismonM. L.HughesC. W.CornersC. K.EmslieG. J.JensenP. S.. . . LopezM. (2006). Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 642-657.
20.
SaitoK.WatanabeK. (2008). The guidelines for the diagnosis and treatment of ADHD. Tokyo, Japan: Jiho.
21.
SatohM.ObaraT.NishigoriH.OobaN.MorikawaY.IshikuroM.. . . ManoN. (2016). Prescription in children with pervasive developmental disorders (PDD): A claims data-based study in Japan. World Journal of Pediatrics, 12, 443-449.
22.
SertA.GokcenC.AyparE.OdabasD. (2012). Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder. Cardiology in the Young, 22, 158-161.
23.
ShinJ. Y.RougheadE. E.ParkB. J.PrattN. N. (2016). Cardiovascular safety of methylphenidate among children and young people with attention- deficit hyperactivity disorder (ADHD): Nationwide self controlled case series study. British Medical Journal, 353, 2550-2558.
24.
SongI.ShinY. J. (2016). Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007–2011. Epidemiology and Health, 38, e2016045.
25.
TakahashiS.OhnoY. (2014). Diagnostic and statistical of mental disorders (American Psychiatric Association, Ed., 5th ed.). Tokyo, Japan: Igaku shoin.
26.
TaylorE.DöpfnerM.SergeantJ.AshersonP.BanaschewskiT.BuitelaarJ.. . . ZuddasA. (2004). European clinical guidelines for hyperkinetic disorder—First upgrade [Supplemental material]. European Child & Adolescent Psychiatry, 13, 17-30.
27.
WintersteinA. G.Soria-SaucedoR.GerhardT.CorrellC. U.OlfsonM. (2017). Differential risk of increasing psychotropic polypharmacy use in children diagnosed with ADHD as preschoolers. Journal of Clinical Psychiatry, 78, 774-781.
28.
WooltortonE. (2006). Medications for attention deficit hyperactivity disorder: Cardiovascular concerns. Canadian Medical Association Journal, 175, 29-30.
